E-DRUG: Accelerating pooled licensing of medicines to enhance global production
---------------------------------------------------------------------------
Dear colleagues,
I would like to share with you this new publication about MPP (Lancet):
“Accelerating pooled licensing of medicines to enhance global production and equitable access” by prof Ken Shadlen:
https://doi.org/10.1016/S0140-6736(22)01013-3
Introduction
From October to November, 2021, the pharmaceutical firms Merck and Pfizer licensed their new COVID-19 oral antiviral medications to the Medicines Patent Pool (MPP).1
In both cases, the drugs were licensed quickly, before they were launched, and the MPP then reached agreements with pharmaceutical firms across the globe (27 firms for Merck’s molnupiravir 2 and 36 firms for Pfizer’s nirmatrelvir 3) to provide generic versions of these to roughly 100 low-income and middle-income countries. This Viewpoint examines the importance of these licences for the global production of, and access to,new medicines, during the pandemic and beyond.
Best, Elize
Elize Massard
Medicines Patent Pool
Elize Massard <emassard@gmail.com>